Sukumar Nagendran Sells 1,780 Shares of AveXis, Inc. (AVXS) Stock
AveXis, Inc. (NASDAQ:AVXS) VP Sukumar Nagendran sold 1,780 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $101.26, for a total transaction of $180,242.80. Following the transaction, the vice president now directly owns 1,780 shares in the company, valued at $180,242.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Sukumar Nagendran also recently made the following trade(s):
- On Monday, October 2nd, Sukumar Nagendran sold 1,780 shares of AveXis stock. The shares were sold at an average price of $97.25, for a total transaction of $173,105.00.
- On Friday, September 1st, Sukumar Nagendran sold 1,780 shares of AveXis stock. The shares were sold at an average price of $93.25, for a total transaction of $165,985.00.
AveXis, Inc. (AVXS) traded up $4.61 on Friday, reaching $104.53. 321,612 shares of the company’s stock were exchanged, compared to its average volume of 323,659.
AveXis (NASDAQ:AVXS) last released its quarterly earnings data on Thursday, August 10th. The company reported ($2.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($1.10). During the same quarter in the prior year, the firm earned ($0.68) EPS. analysts predict that AveXis, Inc. will post -5.55 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Strs Ohio purchased a new position in AveXis in the third quarter valued at $116,000. Botty Investors LLC acquired a new stake in shares of AveXis in the second quarter valued at about $123,000. Ameritas Investment Partners Inc. grew its position in shares of AveXis by 331.0% in the second quarter. Ameritas Investment Partners Inc. now owns 2,112 shares of the company’s stock valued at $174,000 after purchasing an additional 1,622 shares during the period. Deschutes Portfolio Strategy LLC acquired a new stake in shares of AveXis in the third quarter valued at about $203,000. Finally, Seven Bridges Advisors LLC grew its position in shares of AveXis by 49.4% in the second quarter. Seven Bridges Advisors LLC now owns 2,557 shares of the company’s stock valued at $210,000 after purchasing an additional 846 shares during the period. 94.71% of the stock is owned by institutional investors.
AVXS has been the topic of a number of recent research reports. BMO Capital Markets reiterated a “buy” rating and set a $123.00 price objective on shares of AveXis in a research note on Friday, August 11th. Zacks Investment Research upgraded shares of AveXis from a “sell” rating to a “hold” rating in a research note on Thursday, July 13th. Morgan Stanley reiterated an “overweight” rating and set a $118.00 price objective on shares of AveXis in a research note on Wednesday, August 9th. Wells Fargo & Company reiterated an “outperform” rating and set a $134.00 price objective (up from $89.00) on shares of AveXis in a research note on Tuesday, September 5th. Finally, Evercore ISI began coverage on shares of AveXis in a research note on Wednesday, August 16th. They set an “outperform” rating and a $120.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and twelve have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $107.78.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.